- Home
- SAGE
as 07-26-2024 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Upcoming Earnings Alert:
Get ready for potential market movements as Sage Therapeutics Inc. SAGE prepares to release earnings report on 31 Jul 2024.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 648.8M | IPO Year: | 2014 |
| Target Price: | $17.44 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Hold | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.73 - $37.17 | Next Earning Date: | 07-31-2024 |
| Revenue: | $91,064,000 | Revenue Growth: | 868.87% |
| Revenue Growth (this year): | -50.09% | Revenue Growth (next year): | 209.57% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
MT Newswires
a day ago
Baird Adjusts Price Target on Sage Therapeutics to $13 From $15, Maintains Neutral Rating
Zacks
a day ago
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
MT Newswires
2 days ago
Morgan Stanley Halves Price Target on Sage Therapeutics to $11 From $22, Keeps Equalweight Rating
MT Newswires
2 days ago
JPMorgan Downgrades Sage Therapeutics to Neutral From Overweight, Adjusts Price Target to $12 From $18
Clinical Trials Arena
2 days ago
Sage and Biogen’s SAGE-324 shows no benefit in essential tremor trial
Investor's Business Daily
2 days ago
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
MT Newswires
2 days ago
Sage Therapeutics, Biogen Stop Development of Investigational Drug for Essential Tremor
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.